Shareholder Tools

Press Releases

2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1999
Press Releases
Date Title and Summary View
Jun 20, 2016 WEST LAFAYETTE, Ind., June 20, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Mike Sherman has been appointed president and chief executive officer of the Company and added to its board of dire...
May 26, 2016 WEST LAFAYETTE, Ind., May 26, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2016 American Society of...
May 4, 2016 - Data from Phase 1 Dose Escalation Studies of EC1456 and EC1169 to be Presented at ASCO - - Expansion Phase of Trials in Targeted Patients Expected to Yield Efficacy Data in 2016 -- Promising Preclinical Data Demonstrates Unique SMDC Applications in Immuno-Oncology -       - Conference Call Today at 8:30 a.m. EDT - WEST LAFAYETTE, Ind., May 04...
Apr 27, 2016 WEST LAFAYETTE, Ind., April 27, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 4th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast ...
Apr 19, 2016 Poster demonstrates novel approach to a universal T cell overcoming key challenges of current chimeric antigen receptor (CAR) technologies/therapies Potentially meaningful application of SMDC platform in immuno-oncology WEST LAFAYETTE, Ind., April 19, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small mo...
Apr 11, 2016 WEST LAFAYETTE, Ind., April 11, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annua...
Mar 2, 2016 - EC1456 and EC1169 Advance in Phase 1 Dose Escalation Studies - - Expansion Phase of Trials in Targeted Patients Expected to Yield Efficacy Data in 2016 -- Two New Clinical Development Candidates to be Announced in 2016 - - Conference Call Today at 4:30 p.m. EST - WEST LAFAYETTE, Ind., March 02, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDA...
Feb 24, 2016 WEST LAFAYETTE, Ind., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, Mar. 2, at 4:30 p.m. EST to discuss its fourth quarter and full year financial results and provide an operational update. Investors and the general public are invited to listen to a ...
Feb 16, 2016 WEST LAFAYETTE, Ind., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the following upcoming healthcare conferences. 2016 RBC Capital ...
Nov 3, 2015 - Dose Escalation for EC1456 and EC1169 Advance in Phase 1 Studies - - Conference Call Today at 4:30 p.m. EST - WEST LAFAYETTE, Ind., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today annou...
1
... NextLast
Add to Briefcase = add release to Briefcase